{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-12-005",
    "source_story_id": "tmp-story-telmisartan-olaparib-trials",
    "edition_id": "mp-2026-07-12-morning-0003",
    "edition_url": "https://themachinepress.com/edition/2026-07-12",
    "position": 5,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A Blood-Pressure Drug Gives Olaparib a Wider Test",
    "slug": "a-blood-pressure-drug-gives-olaparib-a-wider-test",
    "dek": "Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.",
    "summary": "Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.",
    "body_text": "Dartmouth Cancer Center researchers report that telmisartan increased the activity of the PARP inhibitor olaparib in tumors without the homologous-recombination defects that usually predict response. Early human trials are now testing the combination, including in platinum-resistant ovarian cancer. The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing.",
    "why_it_matters": "Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.",
    "limitations": [
      "The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing."
    ],
    "importance": 8,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-12-005/a-blood-pressure-drug-gives-olaparib-a-wider-test",
    "json_url": "https://themachinepress.com/story/mp-2026-07-12-005.json",
    "first_published_at": "2026-07-12T09:00:00.000-04:00",
    "modified_at": "2026-07-12T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-12-005-001",
        "text": "Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.",
        "source_ids": [
          "source-2026-07-12-005"
        ],
        "qualification": "The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing."
      }
    ],
    "source_ids": [
      "source-2026-07-12-005"
    ],
    "tags": [
      "a",
      "blood",
      "pressure",
      "drug",
      "gives"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-12-005",
      "title": "ScienceDaily from Dartmouth Health",
      "publisher": "www.sciencedaily.com",
      "url": "https://www.sciencedaily.com/releases/2026/07/260709160648.htm",
      "canonical_url": "https://www.sciencedaily.com/releases/2026/07/260709160648.htm",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": "2026-07-10T20:00:00.000-04:00",
      "accessed_at": "2026-07-12T08:25:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-12-005-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A Blood-Pressure Drug Gives Olaparib a Wider Test",
    "publisher": "The Machine Press",
    "published_at": "2026-07-12T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-12-005/a-blood-pressure-drug-gives-olaparib-a-wider-test"
  }
}